Search

Search Constraints

You searched for: Author/Creator Cybulska-Stopa, Bożena

Search Results

1. Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. Issue 1 (February 2021)

2. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

3. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

4. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

5. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

6. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

7. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

8. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Issue 5 (October 2020)

9. Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. (19th May 2022)

10. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. Issue 5 (October 2018)